Selected work
Client results
Barrier and Driver Analysis
Reading adoption risk before launch in an established treatment field
A launch plan built on how clinicians would really prescribe, not on trial data alone.
Hilde Gerris Krol
Partner · Rare disease and medical affairs
Learn more
TPP Validation
When the intelligence says stop
A Phase 3 go/no-go decision that rested on evidence, not optimism.
Jochem Bossenbroek
Partner · Life-sciences ventures and strategy
Learn more
Rare Disease Landscaping and Stakeholder Mapping
Choosing the next indication on ecosystem readiness, not internal familiarity
The next indication chosen on ecosystem readiness, with a basis the team could defend.
Hilde Gerris Krol
Partner · Rare disease and medical affairs
Learn more
Rare Disease Landscaping and Stakeholder Mapping
Mapping the real decision unit across five European markets
A product positioned for European launch around who actually decides, country by country.
Hilde Gerris Krol
Partner · Rare disease and medical affairs
Learn more
Ecosystem Readiness Support
Country launch readiness for a newly EMA-approved oncology therapy
One readiness assessment answering the three questions a newly approved therapy faced at country level.
Patrick de Boer
Advisor · Adoption and AI diagnostics
Learn more
Discuss your research needs
Tell us the disease area, the priority markets and the decision in front of you, and we will come back to you.